AKT1 and non-small cell lung carcinoma: This concurs with previous studies, which reported that IL-6R and AXL, essential promoters of EMT in NSCLC through the STAT3 and the PI3K/AKT signaling pathways [31], are potential targets repressed by miR-155 [32].